Patents by Inventor PATRICE VIDAL

PATRICE VIDAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C-TERMINAL TRUNCATED GDE FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE III
    Publication number: 20230313152
    Abstract: The present invention relates to a functional C-terminal truncated GDE polypeptide for the treatment of glycogen storage disease III.
    Type: Application
    Filed: August 23, 2021
    Publication date: October 5, 2023
    Inventors: GIUSEPPE RONZITTI, PATRICE VIDAL
  • TREATMENT OF GLYCOGEN STORAGE DISEASE III
    Publication number: 20230190965
    Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.
    Type: Application
    Filed: October 25, 2022
    Publication date: June 22, 2023
    Inventors: FEDERICO MINGOZZI, GIUSEPPE RONZITTI, PATRICE VIDAL
  • Treatment of glycogen storage disease III
    Patent number: 11541131
    Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: January 3, 2023
    Assignees: GENETHON, UNIVERSITE D'EVRY VAL D'ESSONNE, INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, SORBONNE UNIVERSITÉ
    Inventors: Federico Mingozzi, Giuseppe Ronzitti, Patrice Vidal
  • New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy
    Publication number: 20220280655
    Abstract: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations.
    Type: Application
    Filed: April 23, 2020
    Publication date: September 8, 2022
    Applicants: Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Genethon, Sorbonne Université, Universite de Paris, Université d'Evry-Val-d'Essonne, Universite Paris XIII Paris-Nord Villetaneuse
    Inventors: Jessica Zucman-Rossi, Jean-Charles Nault, Tiziana La Bella, Giuseppe Ronzitti, Sandrine Imbeaud, Patrice Vidal
  • Peptide-Modified Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism and Increased Muscle Transduction
    Publication number: 20220228167
    Abstract: The invention relates to a recombinant adeno-associated virus (AAV) capsid protein, which is a peptide-modified hybrid between AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74) capsid proteins comprising at least one copy of a peptide comprising the RGD motif, wherein said recombinant peptide-modified hybrid AAV capsid protein has a further reduced liver tropism and an increased muscle transduction compared to the recombinant hybrid AAV capsid protein not having said peptide. The invention relates also to the derived peptide-modified hybrid AAV serotype vector particles packaging a gene of interest and their use in gene therapy, in particular for treating neuromuscular genetic diseases, in particular muscular genetic diseases.
    Type: Application
    Filed: October 4, 2019
    Publication date: July 21, 2022
    Applicants: Genethon, Institut National de la Sante et de la Recherche Medicale, Universite d'Evry Val d'Essonne, Sorbonne Universite, Association Institut de Myologie
    Inventors: Giuseppe RONZITTI, Patrice VIDAL, Federico MINGOZZI
  • HYBRID PROMOTERS FOR MUSCLE EXPRESSION
    Publication number: 20220162640
    Abstract: The present invention relates to hybrid promoters to drive gene expression in muscles.
    Type: Application
    Filed: April 7, 2020
    Publication date: May 26, 2022
    Inventors: GIUSEPPE RONZITTI, PATRICE VIDAL, FEDERICO MINGOZZI
  • MINI-GDE FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE III
    Publication number: 20210292724
    Abstract: The present invention relates to a mini-GDE for the treatment of glycogen storage disease III.
    Type: Application
    Filed: August 6, 2019
    Publication date: September 23, 2021
    Inventors: GIUSEPPE RONZITTI, PATRICE VIDAL, FEDERICO MINGOZZI
  • Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism
    Publication number: 20210107948
    Abstract: The invention relates to a recombinant adeno-associated virus (AAV) capsid protein, which is a hybrid between AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74) capsid proteins, wherein said recombinant hybrid AAV capsid protein has a reduced liver tropism compared to the parent AAV9 and AAVrh74 capsid proteins. The invention relates also to the derived hybrid AAV serotype vector particles packaging a gene of interest and their use in gene therapy, in particular for treating neuromuscular genetic diseases.
    Type: Application
    Filed: April 4, 2019
    Publication date: April 15, 2021
    Applicants: Genethon, INSERM (Institut National de la Santé et de la Recherche Médicale), Universite d'Evry Val d'Essonne, Sorbonne Universite, Association Institut de Myologie
    Inventors: Isabelle RICHARD, Evelyne GICQUEL, Frederico MINGOZZI, Giuseppe RONZITTI, Patrice VIDAL
  • TREATMENT OF GLYCOGEN STORAGE DISEASE III
    Publication number: 20200289673
    Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.
    Type: Application
    Filed: March 9, 2018
    Publication date: September 17, 2020
    Inventors: FEDERICO MINGOZZI, GIUSEPPE RONZITTI, PATRICE VIDAL